Lactobacillus reuteri
probiotic_strainAlso known as: L. reuteri, Limosilactobacillus reuteri, DSM 17938, ATCC 55730, BioGaia
About
Lactobacillus reuteri is one of the few probiotic species that naturally colonizes the human GI tract from infancy. It produces reuterin, a broad-spectrum antimicrobial compound, and research suggests it may help support gastric motility and reduce visceral discomfort through TRPV1 channel modulation. The DSM 17938 strain has been extensively studied for supporting comfort in colicky infants.
How It Works
Produces reuterin, a broad-spectrum antimicrobial compound (3-hydroxypropionaldehyde); accelerates gastric emptying via enteric nervous system modulation; reduces visceral pain through TRPV1 channel modulation; modulates gut motility and colonic transit.
Evidence For Conditions
| Condition | Grade | Studies | Participants | |
|---|---|---|---|---|
| Bloating and Intestinal Gas | B | 7 | 500 | View → |
| Gastroesophageal Reflux Disease (GERD) | C | 2 | 250 | View → |
Side Effects
- Mild gas in initial days of use
- Occasional increased fussiness in infants during adjustment (transient)
- Rare loose stools
- Very rare: bacteremia in immunocompromised individuals
Drug & Supplement Interactions
- Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- Immunosuppressants (theoretical risk in immunocompromised patients)
- Proton pump inhibitors (altered gastric pH may affect colonization)
Always inform your healthcare provider about all supplements you take.
Related Ingredients
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.